These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32116806)

  • 21. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
    Barnett BS; Greer GR
    J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The association between naturalistic use of psychedelics and co-occurring substance use disorders.
    Rabinowitz J; Lev-Ran S; Gross R
    Front Psychiatry; 2022; 13():1066369. PubMed ID: 36704738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations between lifetime classic psychedelic use and cardiometabolic diseases.
    Simonsson O; Osika W; Carhart-Harris R; Hendricks PS
    Sci Rep; 2021 Jul; 11(1):14427. PubMed ID: 34257396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psilocybin use is associated with lowered odds of crime arrests in US adults: A replication and extension.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):66-73. PubMed ID: 35090364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in the Top-Cited Articles on Classic Psychedelics.
    Lawrence DW; Sharma B; Griffiths RR; Carhart-Harris R
    J Psychoactive Drugs; 2021; 53(4):283-298. PubMed ID: 33535907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.
    Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB
    J Affect Disord; 2023 Apr; 326():105-110. PubMed ID: 36720405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines.
    Palamar JJ; Acosta P
    Hum Psychopharmacol; 2020 Jan; 35(1):e2719. PubMed ID: 31909513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.
    Perkins D; Sarris J; Rossell S; Bonomo Y; Forbes D; Davey C; Hoyer D; Loo C; Murray G; Hood S; Schubert V; Galvão-Coelho NL; O'Donnell M; Carter O; Liknaitzky P; Williams M; Siskind D; Penington D; Berk M; Castle D
    Aust N Z J Psychiatry; 2021 Dec; 55(12):1127-1133. PubMed ID: 33745287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample.
    Jones G; Lipson J; Wang E
    Sci Rep; 2023 Feb; 13(1):2466. PubMed ID: 36774449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specificity of the antibody receptor site to D-lysergamide: model of a physiological receptor for lysergic acid diethylamide.
    Van Vunakis H; Farrow JT; Gjika HB; Levine L
    Proc Natl Acad Sci U S A; 1971 Jul; 68(7):1483-7. PubMed ID: 5283939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minorities' Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians.
    Vina SM
    J Racial Ethn Health Disparities; 2024 May; ():. PubMed ID: 38753105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychedelic-Assisted Group Therapy: A Systematic Review.
    Trope A; Anderson BT; Hooker AR; Glick G; Stauffer C; Woolley JD
    J Psychoactive Drugs; 2019; 51(2):174-188. PubMed ID: 30950777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension.
    Jones GM; Ricard JA; Nock MK
    Front Psychiatry; 2024; 15():1169686. PubMed ID: 38979507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classic Psychedelics and Human-Animal Relations.
    Pöllänen E; Osika W; Stenfors CUD; Simonsson O
    Int J Environ Res Public Health; 2022 Jul; 19(13):. PubMed ID: 35805769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychedelics in the treatment of unipolar and bipolar depression.
    Bosch OG; Halm S; Seifritz E
    Int J Bipolar Disord; 2022 Jul; 10(1):18. PubMed ID: 35788817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychedelics and workplace harm.
    Viña SM; Stephens AL
    Front Psychiatry; 2023; 14():1186541. PubMed ID: 37398579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.